Disclosed is the crystalline succinate salt of the compound 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline. Further disclosed is a pharmaceutical composition comprising the succinate salt as defined above , and a pharmaceutically acceptable carrier for treating psychotic disorders, delusional disorders and drug induced psychosis anxiety disorders, movement disorders, mood disorders, neurodegenerative disorders and drug addiction.